SEC Form 4 · accession 0001209191-16-155736
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Dec 14, 2016
Accepted (ET)
Dec 16, 2016 · 7:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2016 | F | 3,229 | $16.70 | D | 31,812 | D | |
| Common StockF2 | Dec 15, 2016 | A | 36,000 | $0.00 | A | 67,812 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents 3,229 shares withheld by and surrendered to the Issuer on December 14, 2016, to satisfy tax withholding obligations that arose in connection with the vesting of 8,594 shares subject to the restricted stock award.
- F2The restricted stock award shall vest in three (3) equal annual installments beginning on January 15, 2018, subject to Dr. Joshi's Continuous Service (as defined by the Issuer's 2014 Equity Incentive Plan) on each vesting date.